300298 三诺生物
午间休市 03-20 11:30:00
资讯
新帖
简况
三诺生物：公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理
证券之星 · 03-17 20:52
三诺生物：公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理
三诺生物：公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请
证券之星 · 03-16
三诺生物：公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请
股市必读：三诺生物（300298）3月5日董秘有最新回复
证券之星 · 03-06
股市必读：三诺生物（300298）3月5日董秘有最新回复
三诺生物：2025年上半年血压计业务实现收入0.93亿元，同比增长50%
证券之星 · 03-04
三诺生物：2025年上半年血压计业务实现收入0.93亿元，同比增长50%
股市必读：三诺生物（300298）3月3日董秘有最新回复
证券之星 · 03-04
股市必读：三诺生物（300298）3月3日董秘有最新回复
三诺生物：2025年上半年海外营收9.97亿元
中金财经 · 02-28
三诺生物：2025年上半年海外营收9.97亿元
三诺生物：公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证
证券之星 · 02-27
三诺生物：公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证
三诺生物（300298）披露取得五项医疗器械注册证暨注册变更公告，2月26日股价下跌1.54%
证券之星 · 02-26
三诺生物（300298）披露取得五项医疗器械注册证暨注册变更公告，2月26日股价下跌1.54%
三诺生物（300298）披露股份回购结果暨股份变动公告，2月24日股价上涨0.22%
证券之星 · 02-24
三诺生物（300298）披露股份回购结果暨股份变动公告，2月24日股价上涨0.22%
三诺生物：统筹考虑是否在PWS精准可穿戴产品管线中进行布局
证券之星 · 02-24
三诺生物：统筹考虑是否在PWS精准可穿戴产品管线中进行布局
三诺生物：不向下修正“三诺转债”转股价格
证券之星 · 02-24
三诺生物：不向下修正“三诺转债”转股价格
三诺生物：持续探索和优化市值管理的方式与路径
证券之星 · 02-10
三诺生物：持续探索和优化市值管理的方式与路径
股市必读：三诺生物（300298）2月6日董秘有最新回复
证券之星 · 02-09
股市必读：三诺生物（300298）2月6日董秘有最新回复
三诺生物：三诺全球研发中心项目在有序建设中
证券之星 · 02-06
三诺生物：三诺全球研发中心项目在有序建设中
股市必读：三诺生物（300298）2月5日董秘有最新回复
证券之星 · 02-06
股市必读：三诺生物（300298）2月5日董秘有最新回复
三诺生物（300298）披露三诺转债回售第三次提示性公告，2月5日股价上涨0.28%
证券之星 · 02-05
三诺生物（300298）披露三诺转债回售第三次提示性公告，2月5日股价上涨0.28%
三诺生物：目前公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理，暂未涉及脑机接口应用
证券之星 · 02-04
三诺生物：目前公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理，暂未涉及脑机接口应用
三诺生物（300298）披露回购公司部分股份进展公告，2月3日股价上涨2.43%
证券之星 · 02-03
三诺生物（300298）披露回购公司部分股份进展公告，2月3日股价上涨2.43%
三诺生物：公司生产经营一切正常
证券之星 · 02-03
三诺生物：公司生产经营一切正常
三诺生物（300298）披露副董事长兼总经理增持公司股份公告，1月30日股价下跌2.66%
证券之星 · 01-30
三诺生物（300298）披露副董事长兼总经理增持公司股份公告，1月30日股价下跌2.66%
加载更多
公司概况
公司名称：
三诺生物传感股份有限公司
所属行业：
专用设备制造业
上市日期：
2012-03-19
主营业务：
三诺生物传感股份有限公司的主营业务是血糖监测系统的生产和销售。公司的主要产品是血糖监测系统、糖化血红蛋白检测系统、血脂检测系统、血压计。公司作为血糖监测领域领先企业，相继获得国内外权威机构的高度认可和荣誉。荣获“国家企业技术中心”、“国家工程研究中心”、“国家技术创新示范企业”、“国家知识产权优势企业”、“国家科技进步二等奖”和“国家绿色工厂”等资质。
发行价格：
29.00
{"stockData":{"symbol":"300298","market":"SZ","secType":"STK","nameCN":"三诺生物","latestPrice":16.45,"timestamp":1773978528000,"preClose":16.56,"halted":0,"volume":2361600,"delay":0,"changeRate":-0.0066,"floatShares":451000000,"shares":560000000,"eps":0.5033,"marketStatus":"午间休市","change":-0.11,"latestTime":"03-20 11:30:00","open":16.61,"high":16.64,"low":16.35,"amount":38881700,"amplitude":0.0175,"askPrice":16.46,"askSize":2,"bidPrice":16.44,"bidSize":14,"shortable":0,"etf":0,"ttmEps":0.5033,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773982800000},"marketStatusCode":3,"adr":0,"adjPreClose":16.56,"symbolType":"stock","openAndCloseTimeList":[[1773970200000,1773977400000],[1773982800000,1773990000000]],"highLimit":18.22,"lowLimit":14.9,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":560267306,"isCdr":false,"pbRate":2.9,"roa":"--","peRate":32.684284,"roe":"6.28%","epsLYR":0.589,"committee":-0.685221,"marketValue":9216000000,"turnoverRate":0.0052,"status":1,"floatMarketCap":7424000000},"requestUrl":"/m/hq/s/300298","defaultTab":"news","newsList":[{"id":"2620427819","title":"三诺生物：公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427819?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751957,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物03月16日在投资者关系平台上答复投资者关心的问题。公司始终坚守全球领先的糖尿病数字管理专家的战略定位，目前公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理，暂未涉及脑机接口应用。公司二代CGM产品暂未向美国FDA正式提交注册申请，目前正按计划推进相关注册筹备工作，后续如有重大进展，公司将严格按照监管要求及时履行信息披露义务。感谢您对公司的关注！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300298","BK0102","BK0114"],"gpt_icon":0},{"id":"2619450924","title":"三诺生物：公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619450924?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:39","pubTimestamp":1773661144,"startTime":"0","endTime":"0","summary":"公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请，目前正按计划推进相关注册筹备工作。鉴于二代 CGM 尚未正式提交美国 FDA 注册申请，且 FDA 医疗器械注册审核流程受产品技术特点、审核反馈、资料补充进度等多重因素影响，评审周期及最终注册结果均存在较大不确定性。因此，公司暂无法预测产品获批时间，后续如有重大进展，公司将严格按照相关法律法规和监管要求，及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600030667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300298","BK0102","BK0114"],"gpt_icon":0},{"id":"2617520802","title":"股市必读：三诺生物（300298）3月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617520802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617520802?lang=zh_cn&edition=full","pubTime":"2026-03-06 02:12","pubTimestamp":1772734334,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，三诺生物报收于16.89元，上涨0.96%，换手率0.83%，成交量3.76万手，成交额6340.61万元。董秘最新回复投资者： 刘烈宏局长近期强调要“加快建设一批数据领域重点实验室”。请问在这两大国家级平台中，三诺分别承担了哪些具体任务？当日关注点来自交易信息汇总：3月5日主力资金净流入34.36万元，游资积极介入，散户资金呈净流出态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600001139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300298","BK0102","BK0114"],"gpt_icon":0},{"id":"2616558553","title":"三诺生物：2025年上半年血压计业务实现收入0.93亿元，同比增长50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558553","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616558553?lang=zh_cn&edition=full","pubTime":"2026-03-04 20:54","pubTimestamp":1772628861,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物03月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，商务部数据显示今年年货期间智能血压仪血糖仪销售额增长超60%，反映健康消费需求旺盛。查阅公司财报，2024年血压计业务实现收入1.23亿元，同比增长10.61%。公司 2025年上半年血压计业务实现收入0.93 亿元，同比增长 50%，整体保持稳健发展态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400038188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","300298","BK0251","BK0102"],"gpt_icon":0},{"id":"2616037607","title":"股市必读：三诺生物（300298）3月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2616037607","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616037607?lang=zh_cn&edition=full","pubTime":"2026-03-04 03:54","pubTimestamp":1772567651,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，三诺生物报收于17.08元，下跌1.1%，换手率1.41%，成交量6.35万手，成交额1.09亿元。董秘最新回复投资者： 董秘您好，面对春节消费中智能健康设备需求旺盛的趋势，30家机构预测公司2026年归母净利润有望同比增长65.11%，主要受益于CGM放量和海外业务改善。当日关注点来自交易信息汇总：3月3日主力资金净流出134.85万元，散户资金净流入563.86万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400004960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","300298","BK0251"],"gpt_icon":0},{"id":"2614815070","title":"三诺生物：2025年上半年海外营收9.97亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614815070","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614815070?lang=zh_cn&edition=full","pubTime":"2026-02-28 17:41","pubTimestamp":1772271665,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月28日在投资者关系平台上答复投资者关心的问题。公司已构建全球化的销售体系，业务覆盖超过180个国家及地区，海外市场已成为公司收入的重要组成。2025年上半年，公司实现海外地区营业收入9.97亿元，海外收入占比达到44.06%。关于具体国家的销售情况，请以公司后续发布的定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260228/32034953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300298"],"gpt_icon":0},{"id":"2614834441","title":"三诺生物：公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2614834441","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614834441?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:42","pubTimestamp":1772188936,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月27日在投资者关系平台上答复投资者关心的问题。公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证，并在2025年开始在国内上市销售。目前正在积极推进全球多国的注册工作。公司已建成CGM半自动化和全自动化生产线，未来将根据CGM产品业务发展情况及销售需求对产量进行动态调整，以满足国内外市场需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700033980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0251","BK0114","BK1222","BK1583","BK1574","09997","BK1100","09996","BK0102","159883"],"gpt_icon":0},{"id":"2614693023","title":"三诺生物（300298）披露取得五项医疗器械注册证暨注册变更公告，2月26日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614693023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614693023?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:45","pubTimestamp":1772117116,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，三诺生物报收于17.91元，较前一交易日下跌1.54%，最新总市值为100.34亿元。该股当日开盘18.14元，最高18.41元，最低17.88元，成交额达1.39亿元，换手率为1.71%。近日，三诺生物传感股份有限公司获得湖南省药品监督管理局颁发的五项医疗器械注册证和一项医疗器械变更注册文件。上述注册证的取得丰富了公司检测产品线，提升了产品技术性能，有助于增强市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK0251","BK1222","BK1583","09997","BK0102","09996","300298","BK0114","BK1100","BK1574"],"gpt_icon":0},{"id":"2613169792","title":"三诺生物（300298）披露股份回购结果暨股份变动公告，2月24日股价上涨0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613169792","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613169792?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:18","pubTimestamp":1771928339,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，三诺生物报收于17.97元，较前一交易日上涨0.22%，最新总市值为100.68亿元。公司于近日披露《关于股份回购结果暨股份变动的公告》。公告显示，三诺生物传感股份有限公司于2025年2月20日审议通过回购公司部分股份方案，拟使用自有资金及专项贷款以集中竞价方式回购股份，用于员工持股计划、股权激励或转换可转债。已回购股份将存放于专用账户，36个月内用于指定用途，否则将注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400035844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","300298","BK0102","BK0251"],"gpt_icon":0},{"id":"2613923737","title":"三诺生物：统筹考虑是否在PWS精准可穿戴产品管线中进行布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2613923737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613923737?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:12","pubTimestamp":1771927928,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月24日在投资者关系平台上答复投资者关心的问题。从生理机制而言，尿酸波动没有血糖波动频繁，其水平变化更多反映的是人体代谢平衡状态，日内波动相对平缓，但这并不意味着持续监测没有价值。如果市场对动态尿酸监测存在真实且明确的需求，公司将结合相关技术成熟度，统筹考虑是否在PWS精准可穿戴产品管线中进行布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400034802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","300298","BK0251"],"gpt_icon":0},{"id":"2613962387","title":"三诺生物：不向下修正“三诺转债”转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2613962387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613962387?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:00","pubTimestamp":1771923647,"startTime":"0","endTime":"0","summary":"结合公司的经营实际、市场环境、股价走势等多重因素，公司董事会决定不向下修正“三诺转债”转股价格，是基于对公司的长期发展潜力与内在价值的信心，切实维护全体股东和债权人的整体和长远利益，同时明确投资者预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400031209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0102","BK0114","BK0251"],"gpt_icon":0},{"id":"2610640466","title":"三诺生物：持续探索和优化市值管理的方式与路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610640466?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:51","pubTimestamp":1770727903,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月09日在投资者关系平台上答复投资者关心的问题。管理层通过增持、高价回购及拒绝下修转股价，清晰传达了认为股价严重低估的信心。针对您的建议，公司高度重视并认真听取各方意见，将在严格遵守信息披露规范的前提下，持续探索和优化市值管理的方式与路径，不断优化投资者沟通机制，综合评估并完善投资者回报机制，引导公司的市场价值与内在价值趋同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000036791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0114","BK0102","300298"],"gpt_icon":0},{"id":"2610577183","title":"股市必读：三诺生物（300298）2月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2610577183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610577183?lang=zh_cn&edition=full","pubTime":"2026-02-09 02:05","pubTimestamp":1770573913,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，三诺生物报收于18.23元，上涨0.22%，换手率1.21%，成交量5.48万手，成交额9985.28万元。随着项目建成，三诺生物的产品iCARE、iCGMS将逐步实现规模化生产，预计年产值达30亿元，税收贡献增加超2亿元。来自公司公告汇总：三诺转债回售申报期为2026年2月9日至2月13日，回售价格为100.274元/张，当前可转债收盘价高于回售价，回售存在亏损风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900000993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0102","BK0114","BK0251"],"gpt_icon":0},{"id":"2609689615","title":"三诺生物：三诺全球研发中心项目在有序建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2609689615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609689615?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:09","pubTimestamp":1770365352,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月06日在投资者关系平台上答复投资者关心的问题。三诺全球研发中心项目在有序建设中，公司将严格按照项目规划积极推进，后续进展请以公司官方渠道发布的信息为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600024835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300298","BK0114","BK0251"],"gpt_icon":0},{"id":"2609583248","title":"股市必读：三诺生物（300298）2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609583248","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609583248?lang=zh_cn&edition=full","pubTime":"2026-02-06 02:09","pubTimestamp":1770314952,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，三诺生物报收于18.19元，上涨0.28%，换手率1.21%，成交量5.47万手，成交额9924.95万元。来自公司公告汇总：三诺转债触发回售条款，回售申报期为2026年2月9日至2月13日，回售价格为100.274元/张，当前市价高于回售价，回售存在亏损风险。三诺转债因公司股票连续三十个交易日收盘价低于当期转股价格的70%，触发有条件回售条款。回售期间三诺转债暂停转股，持有人可自主选择是否回售，不具强制性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0114","BK0102","300298"],"gpt_icon":0},{"id":"2609013343","title":"三诺生物（300298）披露三诺转债回售第三次提示性公告，2月5日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609013343","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609013343?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:35","pubTimestamp":1770302120,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，三诺生物报收于18.19元，较前一交易日上涨0.28%，最新总市值为101.91亿元。该股当日开盘18.1元，最高18.24元，最低18.01元，成交额达9924.95万元，换手率为1.21%。近日，三诺生物传感股份有限公司发布关于三诺转债回售的第三次提示性公告。发行人资金到账日为2026年2月26日，回售款划拨日为2月27日，投资者回售款到账日为2026年3月2日。回售期间三诺转债暂停转股。当前可转债收盘价高于回售价格，回售可能存在损失风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0251","BK0102","BK0114"],"gpt_icon":0},{"id":"2608361448","title":"三诺生物：目前公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理，暂未涉及脑机接口应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2608361448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608361448?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:52","pubTimestamp":1770209562,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月03日在投资者关系平台上答复投资者关心的问题。目前，公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理，暂未涉及脑机接口应用。公司将密切关注行业前沿技术的发展与应用，感谢您对公司的关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400039523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0251","300298","BK0102"],"gpt_icon":0},{"id":"2608877699","title":"三诺生物（300298）披露回购公司部分股份进展公告，2月3日股价上涨2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608877699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608877699?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:30","pubTimestamp":1770129042,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，三诺生物报收于18.15元，较前一交易日上涨2.43%，最新总市值为101.69亿元。该股当日开盘17.84元，最高18.18元，最低17.79元，成交额达1.11亿元，换手率为1.36%。近日，三诺生物传感股份有限公司发布《关于回购公司部分股份的进展公告》。公告显示，公司于2025年2月20日审议通过回购公司部分股份方案，拟使用自有资金及银行回购专项贷款，以集中竞价交易方式回购股份，用于员工持股计划、股权激励或转换可转换公司债券。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","300298","BK0251"],"gpt_icon":0},{"id":"2608788648","title":"三诺生物：公司生产经营一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2608788648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608788648?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:27","pubTimestamp":1770118026,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物(300298)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问你公司经营出现了什么问题？就是这样给投资者信心的？恩？三诺生物回复：您好！公司生产经营一切正常，基本面未发生重大变化。关于公司业绩情况，您可查看公司于2026年1月28日在巨潮资讯网上披露的2025年度业绩预告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300037384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0114","BK0251","BK0102"],"gpt_icon":0},{"id":"2607309047","title":"三诺生物（300298）披露副董事长兼总经理增持公司股份公告，1月30日股价下跌2.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607309047","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607309047?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:43","pubTimestamp":1769787791,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，三诺生物报收于17.55元，较前一交易日下跌2.66%，最新总市值为98.33亿元。该股当日开盘17.92元，最高18.0元，最低17.55元，成交额达1.66亿元，换手率为2.08%。近日，三诺生物发布《关于副董事长兼总经理增持公司股份的公告》。本次增持不会导致公司控制权变化，且李心一女士承诺增持后6个月内不减持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","300298","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773978589663,"stockEarnings":[{"period":"1week","weight":-0.0219},{"period":"1month","weight":-0.0764},{"period":"3month","weight":-0.0466},{"period":"6month","weight":-0.1802},{"period":"1year","weight":-0.3206},{"period":"ytd","weight":-0.0321}],"compareEarnings":[{"period":"1week","weight":-0.0297},{"period":"1month","weight":-0.0185},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.1693},{"period":"ytd","weight":0.0095}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三诺生物传感股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"24597人(较上一季度增加58.52%)","perCapita":"18347股","listingDate":"2012-03-19","address":"湖南省长沙市岳麓区高新技术产业开发区谷苑路265号","registeredCapital":"56026万元","survey":" 三诺生物传感股份有限公司的主营业务是血糖监测系统的生产和销售。公司的主要产品是血糖监测系统、糖化血红蛋白检测系统、血脂检测系统、血压计。公司作为血糖监测领域领先企业，相继获得国内外权威机构的高度认可和荣誉。荣获“国家企业技术中心”、“国家工程研究中心”、“国家技术创新示范企业”、“国家知识产权优势企业”、“国家科技进步二等奖”和“国家绿色工厂”等资质。","listedPrice":29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三诺生物(300298)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三诺生物(300298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三诺生物,300298,三诺生物股票,三诺生物股票老虎,三诺生物股票老虎国际,三诺生物行情,三诺生物股票行情,三诺生物股价,三诺生物股市,三诺生物股票价格,三诺生物股票交易,三诺生物股票购买,三诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三诺生物(300298)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三诺生物(300298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}